Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE

SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE

Standard Dose
50MG;500MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 204591 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG Sponsor TEVA PHARMS USA INC Submission history Latest submission status date: 2015-09-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 204591 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG Sponsor TEVA PHARMS USA INC Submission history Latest submission status date: 2015-09-29 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE (SITAGLIPTIN PHOSPHATE;METFORMIN HYDROCHLORIDE) | Drug Monograph | MedicHelpline